at Zacks.com (Thu, 10:51AM)
Celgene (CELG +0.6%) says it's been notified by the FDA that there won't be an Oncologic Drugs Advisory Committee meeting scheduled for November 8. Its review of the company's NDA for pomalidomide will continue with the previously announced PDUFA action date of Feb. 10, 2013. Pomalidomide is a potential blockbuster for CELG, and the company has been hoping for an early approval of of the drug to be used in combination with dexamethasone as a treatment for patients with myeloma.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Zacks.com (Thu, 8:59AM)
at Zacks.com (Tue, 4:45PM)
at Zacks.com (Jan 22, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs